Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 13;27(5):699-703.
doi: 10.1016/j.chom.2020.04.021.

The Challenges of Vaccine Development against a New Virus during a Pandemic

Affiliations

The Challenges of Vaccine Development against a New Virus during a Pandemic

Michael S Diamond et al. Cell Host Microbe. .

Abstract

The rapid emergence of a highly pathogenic, readily transmissible coronavirus has resulted in a global pandemic, affecting millions and destabilizing economies. This catastrophe triggered a clarion call for the immediate deployment of a protective vaccine. We describe the unique challenges of developing a vaccine against SARS-CoV-2 in a pandemic setting.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests M.S.D. is a consultant for Inbios, Vir Biotechnology, and NGM Biopharmaceuticals, and is on the Scientific Advisory Board of Moderna. The Diamond laboratory at Washington University School of Medicine has received sponsored research agreements from Moderna.

Figures

Figure 1
Figure 1
Structure of the SARS-CoV-2 (A) The SARS-CoV-2 is a spherical virus particle that incorporates three structural proteins into its lipid envelope (S, M, and E) and encapsidates a positive-stranded RNA genome in complex with the N protein. (B) The structure of the S protein trimer was solved using cryo-electron microscopy and is shown (PDB: 6VYB) (Wrapp et al., 2020). The RBD (shown in green) may existing in an open or closed (up or down) structural state; the RBD of one of the three S protomers within the trimer is shown in the up position.

References

    1. Bolles M., Deming D., Long K., Agnihothram S., Whitmore A., Ferris M., Funkhouser W., Gralinski L., Totura A., Heise M., Baric R.S. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 2011;85:12201–12215. - PMC - PubMed
    1. de Wit E., van Doremalen N., Falzarano D., Munster V.J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016;14:523–534. - PMC - PubMed
    1. Graham R.L., Donaldson E.F., Baric R.S. A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 2013;11:836–848. - PMC - PubMed
    1. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., China Medical Treatment Expert Group for Covid-19 Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed
    1. Jaume M., Yip M.S., Cheung C.Y., Leung H.L., Li P.H., Kien F., Dutry I., Callendret B., Escriou N., Altmeyer R. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway. J. Virol. 2011;85:10582–10597. - PMC - PubMed

Publication types

MeSH terms